- $1.20tn
- $1.24tn
- $65.18bn
Factbox: Major drugmakers turn to China for licensing deals
Trump Medicare drug pricing model may apply to only four companies after exemptions
Foghorn plunges after scrapping Lilly-backed drug program
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
Brief: Foghorn Therapeutics Provides Update On Fhd-909 And Strategic Priorities
Brief: Eli Lilly - Foundayo 17.2 Mg Associated With 57% Reduction In Diabetes Risk, 18% In Cardiovascular Risk Versus Placebo
Brief: Lilly's Foundayo Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction And Weight Loss
Experimental Lilly combination drug tops Zepbound in weight-loss trial (updated)
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Formulation Product By 2026 End
Experimental Lilly combination drug tops Zepbound in weight-loss trial
Factbox: Major drugmakers turn to China for licensing deals
Patients switching to Novo Nordisk's Wegovy pill from shots lose more weight in real-world study
Lilly's experimental drug cuts weight by 21% in diabetes trial
Brief: Novo Says Ozempic Cuts Risk Of Major Cardiovascular Events
Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro (updated)
Brief: Lilly's Zepbound (Tirzepatide 10 Mg And 15 Mg) Was Associated With More Weight Loss Than Wegovy Hd (Semaglutide Injection 7.2 Mg) In A New Indirect Treatment Comparison
Lilly touts Foundayo advantage over Novo's Ozempic pill in diabetes analysis
Novo Nordisk says Ozempic shows lower risk of cardiovascular events compared to Eli Lilly's Mounjaro